The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
Abstract
Purpose: We assessed outcomes of men with prostate cancer enrolled in active surveillance. Patients and Methods: Since 1995, a total of 769 men diagnosed with prostate cancer have been followed prospectively (median follow-up, 2.7 years; range, 0.01 to 15.0 years) on active surveillance. Enrollment criteria were for very-low-risk cancers, defined by clinical stage (T1c), prostate-specific antigen density < 0.15 ng/mL, and prostate biopsy findings (Gleason score ≤ 6, two or fewer cores with cancer, and ≤ 50% cancer involvement of any core). Curative intervention was recommended on disease reclassification on the basis of biopsy criteria. The primary outcome was survival free of intervention, and secondary outcomes were rates of disease reclassification and exit from the program. Outcomes were compared between men who did and did not meet very-low-risk criteria. Results: The median survival free of intervention was 6.5 years (range, 0.0 to 15.0 years) after diagnosis, and the proportions of men remaining free of intervention after 2, 5, and 10 years of follow-up were 81%, 59%, and 41%, respectively. Overall, 255 men (33.2%) underwent intervention at a median of 2.2 years (range, 0.6 to 10.2 years) after diagnosis; 188 men (73.7%) underwent intervention on the basis of disease reclassification on biopsy. The proportions of men who underwent curative intervention (P = .026) or had biopsy reclassification (P < .001) were significantly lower in men who met enrollment criteria than in those who did not. There were no prostate cancer deaths. Conclusion: For carefully selected men, active surveillance with curative intent appears to be a safe alternative to immediate intervention. Limiting surveillance to very-low-risk patients may reduce the frequency of adverse outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,599
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., & Loblaw, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2180 · Cited by 1,074
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.-G., Stranne, J., Holmberg, E., & Lilja, H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70146-7 · Cited by 936
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationActive surveillance for the management of prostate cancer in a contemporary cohort
Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., et al. (2008) · Cancer · doi:10.1002/cncr.23502 · Cited by 404
The Changing Face of Prostate Cancer
Cooperberg, M. R., Moul, J. W., & Carroll, P. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9751 · Cited by 318
Cited by
Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
The personal and clinical utility of polygenic risk scores
Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0018-x · Cited by 1,623
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
Dall’Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.072 · Cited by 602
Self-citationActive Surveillance for Prostate Cancer: Progress and Promise
Cooperberg, M. R., Carroll, P. R., & Klotz, L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9738 · Cited by 290
Metadata
- Authors
- Tosoian, J. J., Trock, B. J., Landis, P., Feng, Z., Epstein, J. I., Partin, A. W., Walsh, P. C., & Carter, H. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-01
- Volume
- 29
- Issue
- 16
- Pages
- 2185-2190
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102558162
- Cited by
- 596
- References
- 16
- FWCI
- 56.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. https://app.cochat.ai/papers/10.1200/jco.2010.32.8112
- The paper
- Tosoian, J. J., Trock, B. J., Landis, P., Feng, Z., Epstein, J. I., Partin, A. W., Walsh, P. C., & Carter, H. B. (2011). Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.32.8112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.